Document Details
Document Information
5afc286c-8d94-4743-814f-75f75a5ddf97
Novartis IgAN data in New England Journal of Medicine show Fabhalta® slowed kidney function decline
press_release
Communication Type Company CEO Executives CEO
None
2026-03-29
N/A
2324
27870
Actions
Document Content
# Novartis IgAN data in New England Journal of Medicine show Fabhalta® slowed kidney function decline by 49.3% **Date:** 2026-03-29 01:15:00 **Company:** Novartis AG **Ticker:** NVS **Source URL:** https://www.globenewswire.com/news-release/2026/03/29/3264223/0/en/Novartis-IgAN-data-in-New-England-Journal-of-Medicine-show-Fabhalta-slowed-kidney-function-decline-by-49-3.html --- [Accessibility: Skip TopNav](https://www.globenewswire.com/news-release/2026/03/29/3264223/0/en/Novartis-IgAN-data-in-New-England-Journal-of-Medicine-show-Fabhalta-slowed-kidney-function-decline-by-49-3.html#maincontainer) [](https://www.globenewswire.com/) - [Newsroom](https://www.globenewswire.com/newsroom) - [Services](https://www.globenewswire.com/services) - [Contact Us](https://insight.notified.com/globenewswire-contact-us?utm_medium=Website&utm_source=Contact%20Us&utm_campaign=Contact%20Us%20ENG) - [About Us](http...
# Novartis IgAN data in New England Journal of Medicine show Fabhalta® slowed kidney function decline by 49.3% **Date:** 2026-03-29 01:15:00 **Company:** Novartis AG **Ticker:** NVS **Source URL:** https://www.globenewswire.com/news-release/2026/03/29/3264223/0/en/Novartis-IgAN-data-in-New-England-Journal-of-Medicine-show-Fabhalta-slowed-kidney-function-decline-by-49-3.html --- [Accessibility: Skip TopNav](https://www.globenewswire.com/news-release/2026/03/29/3264223/0/en/Novartis-IgAN-data-in-New-England-Journal-of-Medicine-show-Fabhalta-slowed-kidney-function-decline-by-49-3.html#maincontainer) [](https://www.globenewswire.com/) - [Newsroom](https://www.globenewswire.com/newsroom) - [Services](https://www.globenewswire.com/services) - [Contact Us](https://insight.notified.com/globenewswire-contact-us?utm_medium=Website&utm_source=Contact%20Us&utm_campaign=Contact%20Us%20ENG) - [About Us](https://www.globenewswire.com/about) - English [Sign In](https://www.globenewswire.com/home/signin) [Register](https://portal.notified.com/en/registration) # [](https://novartis.com/) # Novartis IgAN data in New England Journal of Medicine show Fabhalta® slowed kidney function decline by 49.3% March 29, 2026 01:15 ET\| Source: [Novartis Pharma AG](https://www.globenewswire.com/en/search/organization/Novartis%2520Pharma%2520%2520AG)FollowNovartis Pharma AG * * * Share - * * * - _Fabhalta lowered likelihood of progression to kidney failure by 43% in APPLAUSE-IgAN study_ _1_ - _40.7% of patients on Fabhalta demonstrated sustained reduction of protein in urine over two years_ _1_ - _Fabhalta granted priority review by FDA for traditional approval_ **Basel, March 29, 2026**– Novartis today announced final two-year results from the Phase III APPLAUSE‑IgAN study of Fabhalta® (iptacopan) in IgA nephropathy (IgAN). Fabhalta demonstrated a statistically significant, clinically meaningful improvement in estimated glomerular filtration rate (eGFR) slope, a key marker of kidney function, compared with placebo1. Fabhalta consistently outperformed placebo across key kidney outcomes over two years, demonstrating a slowing of disease progression and the potential to preserve kidney function in IgAN1. The results were published in the _[New England Journal of Medicine](http://www.nejm.org/doi/full/10.1056/NEJMoa2600743 "New England Journal of Medicine")_ and simultaneously presented as late‑breaking data at the 2026 World Congress of Nephrology (WCN). “Persistent kidney inflammation is a hallmark of IgAN, and a key driver of disease progression, leading to ongoing kidney damage and loss of function over time,” said Vlado Perkovic, MD, Professor of Medicine and Provost, University of New South Wales, and Steering Committee Co‑Chair of the APPLAUSE‑IgAN study. “These results are important because they show that Fabhalta can reduce the risk of disease progression, help preserve kidney health, and address outcomes associated with long-term disease burden.” **Key efficacy results over two years** **1** | | | | | | --- | --- | --- | --- | | **Endpoint** | **Fabhalta** | **Placebo** | **Effect vs. placebo** | | **Kidney function**<br>**(eGFR slope)** | –3.10 mL/min/1.73 m²/yr | –6.12 mL/min/1.73 m²/yr | 3.02 mL/min/1.73 m2/yr (49.3% slower decline) | | **Composite kidney failure events\*†** | 21.4% | 33.5% | HR 0.57 (43% lower likelihood) | | **Proteinuria†**<br>**(24-hour UPCR <1g/g)** | 40.7% achieved target | 23.7% achieved target | — | _\*_ _Composite kidney failure endpoint:_ _reaching either_ _sustained ≥30% decline in eGFR relative to baseline, sustained eGFR <15 mL/min/1.73 m², initiation of maintenance dialysis, kidney transplant, or death from kidney failure_ _†_ _As measured by p_ _ercentage of patient_ _s_ “The two-year results demonstrate that Fabhalta consistently and meaningfully slows kidney function decline in high-risk patients with IgAN,” said Ruchira Glaser, MD, MS, Global Head, Cardiovascular, Renal and Metabolic Development, Novartis. “This progress reflects years of focused research and supports our efforts to advance more targeted treatment options to help preserve kidney health in people living with IgAN.” The safety profile of Fabhalta over two years was consistent with previous findings. Rates of adverse events and treatment discontinuation were low and similar between Fabhalta and placebo1,2. Fabhalta received accelerated approval in the U.S. and China for proteinuria reduction in adults with IgAN based on data from a prespecified interim analysis of the APPLAUSE-IgAN study2,3. The two-year data were submitted to the U.S. Food and Drug Administration for traditional approval. Fabhalta was granted priority review based on the novel mode of action and the strength of the data. Alongside Fabhalta, Novartis continues to advance its multi-asset IgAN portfolio, which also includes Vanrafia® (atrasentan) and investigational compound zigakibart. **About IgAN** IgAN is a progressive autoimmune kidney disease, with approximately 25 people per million worldwide newly diagnosed each year4,5. IgAN is highly debilitating as it leads to inflammation in the small filters of the kidneys, excess protein in urine, and a gradual decline in eGFR6. Up to 50% of patients with persistent proteinuria progress to kidney failure within 10 to 20 years of diagnosis, often requiring dialysis or kidney transplantation as part of long-term disease management5-10. Furthermore, people living with IgAN often face mental and social challenges6-9. Supportive care has not addressed the underlying causes of the disease and often fails to slow disease progression, reinforcing the need for more targeted therapies for IgAN7-12. **About APPLAUSE-IgAN** APPLAUSE-IgAN ( [NCT04578834](https://clinicaltrials.gov/study/NCT04578834 "NCT04578834")) is a global, randomized, double-blind, placebo-controlled Phase III study evaluating Fabhalta in adults with biopsy-confirmed IgAN and persistent proteinuria despite optimized supportive care. Patients were randomized 1:1 to receive Fabhalta or placebo and were followed for up to 24 months11. The primary endpoint was the annualized total eGFR slope over 24 months. Key secondary endpoints included time to first composite kidney failure event and changes in proteinuria over 9 months1. The most common adverse events with Fabhalta were mainly mild-to-moderate infections (such as COVID-19 and upper respiratory tract infection), headache, diarrhea, and hyperlipidemia, with overall adverse event rates comparable to placebo1. **About Fabhalta** **®** **(iptacopan)** Fabhalta (iptacopan) is an oral Factor B inhibitor designed to selectively target the alternative complement pathway, one of several key drivers of inflammation and kidney damage in IgAN4,12,13. By inhibiting Factor B, Fabhalta aims to reduce ongoing complement-mediated injury and slow disease progression. Fabhalta has received regulatory approvals in multiple complement-mediated diseases, including IgAN, and is being evaluated across a range of rare kidney conditions. **Novartis’ commitment to kidney diseases** Building on a legacy of more than 40 years that began in transplant, Novartis is on a mission to empower breakthroughs and transform care in kidney health, starting with kidney conditions that have significant unmet need. Historically, these conditions have had considerably less funding and research, leading to a treatment landscape largely focused on reactive or end-stage disease management, often with significant physical, emotional, and financial burdens. Our portfolio targets the underlying causes of disease, with an aim to protect kidney health and delay or prevent dialysis and/or transplantation. Our goal is to help patients get back to living life on their terms - whether at work, in school, or with loved ones, and by partnering with patients, advocates, clinicians and policymakers, we aim to raise awareness, accelerate diagnosis, and get patients the right care, sooner. **Disclaimer** This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements can generally be identified by words such as “potential,” “can,” “will,” “plan,” “may,” “could,” “would,” “expect,” “anticipate,” “look forward,” “believe,” “committed,” “investigational,” “pipeline,” “launch,” or similar terms, or by express or implied discussions regarding potential marketing approvals, new indications or labeling for the investigational or approved products described in this press release, or regarding potential future revenues from such products. You should not place undue reliance on these statements. Such forward-looking statements are based on our current beliefs and expectations regarding future events, and are subject to significant known and unknown risks and uncertainties. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those set forth in the forward-looking statements. There can be no guarantee that the investigational or approved products described in this press release will be submitted or approved for sale or for any additional indications or labeling in any market, or at any particular time. Nor can there be any guarantee that such products will be commercially successful in the future. In particular, our expectations regarding such products could be affected by, among other things, the uncertainties inherent in research and development, including clinical trial results and additional analysis of existing clinical data; regulatory actions or delays or government regulation generally; global trends toward health care cost containment, including government, payor and general public pricing and reimbursement pressures and requirements for increased pricing transparency; our ability to obtain or maintain proprietary intellectual property protection; the particular prescribing preferences of physicians and patients; general political, economic and business conditions, including the effects of and efforts to mitigate pandemic diseases; safety, quality, data integrity or manufacturing issues; potential or actual data security and data privacy breaches, or disruptions of our information technology systems, and other risks and factors referred to in Novartis AG’s current Form 20-F on file with the US Securities and Exchange Commission. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise. **About Novartis** Novartis is an innovative medicines company. Every day, we work to reimagine medicine to improve and extend people’s lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach more than 300 million people worldwide. Reimagine medicine with us: Visit us at [**https://www.novartis.com**](https://www.novartis.com/ "") and connect with us on [**LinkedIn**](https://www.linkedin.com/company/novartis/ ""), [**Facebook**](https://www.facebook.com/novartis/ ""), [**X/Twitter**](https://twitter.com/Novartis "") and [**Instagram**](https://instagram.com/novartis?igshid=MzRlODBiNWFlZA==__;!!N3hqHg43uw!pjp8z253J5NjaOYrW65UbAAlHeHRdQ-w0m4ezZxEQEl0ptafXN2M99VRIk39pf49PAc8NbK93Pxp3uaSBQkAf8oEnzWXG8Sk$ ""). **References** 01. Novartis. Data on file 02. Novartis Pharmaceuticals Corporation. Novartis receives FDA accelerated approval for Fabhalta® (iptacopan), the first and only complement inhibitor for the reduction of proteinuria in primary IgA nephropathy (IgAN) (2024). Available at: [https://www.novartis.com/news/media-releases/novartis-receives-fda-accelerated-approval-fabhalta-iptacopan-first-and-only-complement-inhibitor-reduction-proteinuria-primary-iga-nephropathy-igan](https://www.novartis.com/news/media-releases/novartis-receives-fda-accelerated-approval-fabhalta-iptacopan-first-and-only-complement-inhibitor-reduction-proteinuria-primary-iga-nephropathy-igan ""). Accessed March 2026 03. Novartis China. Novartis’ innovative medicine Fabhalta® (iptacopan) approved in China for a new indication. Novartis China website (in Mandarin). Available at: [https://www.novartis.com.cn/news/nuohuazaiyingshenzangjibingzhiliaolingyulichengbeichuangxinyaowufeihedayansuanyipukepanjiaonangigashenbingshiyingzhengzaizhongguohuopi](https://www.novartis.com.cn/news/nuohuazaiyingshenzangjibingzhiliaolingyulichengbeichuangxinyaowufeihedayansuanyipukepanjiaonangigashenbingshiyingzhengzaizhongguohuopi ""). Accessed March 2026 04. Rizk DV, Maillard N, Julian BA, et al. The emerging role of complement proteins as a target for therapy of IgA nephropathy. _Front Immunol_ 2019;10:504. 05. Cheung C, Barratt J. The rapidly changing treatment landscape of IgA nephropathy. _Semin Nephrol_. 2025;44:151573. 06. Kwon CS, Daniele P, Forsythe A et al. A systematic literature review of the epidemiology, health-related quality of life impact, and economic burden of immunoglobulin a nephropathy. _J Health Econ Outcomes Res_. 2021;8:36–45. 07. Pitcher D, Braddon F, Hendry B et al. Long-term outcomes in IgAN. _Clin J Am Soc Nephrol_. 2023;18:727–8. 08. Mohd R, Mohammad Kazmin NE, Abdul Cader R, et al. Long-term outcome of immunoglobulin A (IgA) nephropathy: a single center experience. _PLoS One_. 09. National Kidney Foundation. The voice of the patient (2020). Available at: [https://igan.org/wp-content/uploads/2021/01/VOP\_IgAN\_12-7-20\_\_FNL.pdf](https://igan.org/wp-content/uploads/2021/01/VOP_IgAN_12-7-20__FNL.pdf ""). Accessed March 2026. 10. Kidney Disease: Improving Global Outcomes (KDIGO) Glomerular Diseases Work Group. KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases. _Kidney Int_. 2021;100:S1–276. 11. Clinicaltrials.gov. NCT04578834. Study of Efficacy and Safety of LNP023 in Primary IgA Nephropathy Patients (APPLAUSE-IgAN). Available at: [https://clinicaltrials.gov/study/NCT04578834](https://clinicaltrials.gov/study/NCT04578834 ""). Accessed March 2026. 12. Perkovic V, Barratt J, Rovin B, et al. Alternative complement pathway inhibition with iptacopan in IgA nephropathy. _N Engl J Med_. 2025;392:531–543. 13. Chiu YL, Lin WC, Shu KH, et al. Alternative complement pathway is activated and associated with galactose-deficient IgA(1) antibody in IgA nephropathy patients. _Front Immunol_ 2021;12:638309. \# # # | | | | --- | --- | | **Novartis Media Relations**<br> E-mail: [media.relations@novartis.com](mailto:media.relations@novartis.com "media.relations@novartis.com") | | | **Novartis Investor Relations**<br> Central investor relations line: +41 61 324 7944<br> E-mail: [investor.relations@novartis.com](mailto:investor.relations@novartis.com "investor.relations@novartis.com") | |  * * * ## Tags [Media Release](https://www.globenewswire.com/en/search/tag/media%2520release "Media Release")[Clinical Trials](https://www.globenewswire.com/en/search/tag/clinical%2520trials "Clinical Trials")[Rare Diseases](https://www.globenewswire.com/en/search/tag/rare%2520diseases "Rare Diseases")[Reimagine Medicine](https://www.globenewswire.com/en/search/tag/reimagine%2520medicine "Reimagine Medicine") ### Attachments [](https://ml-eu.globenewswire.com/Resource/Download/2f0ce08d-425c-4edb-a0e0-e13b017001fd) Media release (PDF).pdf... GlobeNewswire Company ProfileNovartis Pharma AGIndustry: PharmaceuticalsWebsite: [https://novartis.com](https://novartis.com/) Press Release Actions - [Print](https://www.globenewswire.com/news-release/2026/03/29/3264223/0/en/Novartis-IgAN-data-in-New-England-Journal-of-Medicine-show-Fabhalta-slowed-kidney-function-decline-by-49-3.html?print=1) - [Download PDF](https://www.globenewswire.com/news-release/2026/03/29/3264223/0/en/Novartis-IgAN-data-in-New-England-Journal-of-Medicine-show-Fabhalta-slowed-kidney-function-decline-by-49-3.html?pdf=1) - [Subscribe via RSS](https://www.globenewswire.com/rssfeed/organization/ApPC3aRBom1jeiovES24_w==) - [Subscribe via ATOM](https://www.globenewswire.com/atomfeed/organization/ApPC3aRBom1jeiovES24_w==) - [Javascript](https://www.globenewswire.com/JSWidget/organization/UORR69au9eZIboyb3C5ChA%3d%3d) ## Recommended Reading - March 27, 2026 02:00 ET\|Source: [Novartis Pharma AG](https://www.globenewswire.com/en/search/organization/Novartis%2520Pharma%2520%2520AG) [Novartis agrees to acquire Excellergy, Inc., building on allergy leadership with next-generation anti-IgE innovation](https://www.globenewswire.com/news-release/2026/03/27/3263554/0/en/Novartis-agrees-to-acquire-Excellergy-Inc-building-on-allergy-leadership-with-next-generation-anti-IgE-innovation.html) - Proposed acquisition strengthens Novartis immunology strategy in food allergy and other IgE-driven diseases - Lead asset Exl-111 builds on proven IgE biology with a differentiated mechanism... [Read More](https://www.globenewswire.com/news-release/2026/03/27/3263554/0/en/Novartis-agrees-to-acquire-Excellergy-Inc-building-on-allergy-leadership-with-next-generation-anti-IgE-innovation.html)  - March 23, 2026 02:15 ET\|Source: [Novartis Pharma AG](https://www.globenewswire.com/en/search/organization/Novartis%2520Pharma%2520%2520AG) [Novartis presents new data on early symptom relief and long-term control in complex skin diseases at AAD 2026](https://www.globenewswire.com/news-release/2026/03/23/3260120/0/en/Novartis-presents-new-data-on-early-symptom-relief-and-long-term-control-in-complex-skin-diseases-at-AAD-2026.html) New Rhapsido® REMIX-1 & -2 pooled analysis on symptom control as early as week 1 in chronic spontaneous urticaria (CSU) to be presentedLong-term Cosentyx® data build on extensive body of evidence... [Read More](https://www.globenewswire.com/news-release/2026/03/23/3260120/0/en/Novartis-presents-new-data-on-early-symptom-relief-and-long-term-control-in-complex-skin-diseases-at-AAD-2026.html)  [View More News](https://www.globenewswire.com/en/newsroom) ## Explore Previous [](https://www.globenewswire.com/news-release/2026/03/28/3264174/0/en/Rocket-Lab-Successfully-Launches-85th-Mission-and-First-Dedicated-Launch-for-European-Space-Agency.html) March 28, 2026 06:39 ET [Rocket Lab Successfully Launches 85th Mission and ...](https://www.globenewswire.com/news-release/2026/03/28/3264174/0/en/Rocket-Lab-Successfully-Launches-85th-Mission-and-First-Dedicated-Launch-for-European-Space-Agency.html "Rocket Lab...") [](https://www.globenewswire.com/news-release/2026/03/28/3264171/0/en/Cointelegraph-Research-covers-UNDP-s-new-blockchain-report-on-modernizing-public-infrastructure.html) March 28, 2026 02:35 ET [Cointelegraph Research covers UNDP's new blockchai...](https://www.globenewswire.com/news-release/2026/03/28/3264171/0/en/Cointelegraph-Research-covers-UNDP-s-new-blockchain-report-on-modernizing-public-infrastructure.html "Cointelegraph...") [](https://www.globenewswire.com/news-release/2026/03/28/3264162/0/en/THE-CHAMPIONS-COLLECTIVE-PRESENTS-THE-DODGERS-2025-WORLD-SERIES-RING-FEATURING-GAME-SEVEN-DIRT.html) March 27, 2026 21:56 ET [THE CHAMPIONS COLLECTIVE PRESENTS THE DODGERS’ 202...](https://www.globenewswire.com/news-release/2026/03/28/3264162/0/en/THE-CHAMPIONS-COLLECTIVE-PRESENTS-THE-DODGERS-2025-WORLD-SERIES-RING-FEATURING-GAME-SEVEN-DIRT.html "THE CHAMPIONS...") [](https://www.globenewswire.com/news-release/2026/03/28/3264178/0/en/TitanPlay-Focuses-on-Player-Protection-Through-Culturally-Aware-Responsible-Gambling-Measures.html) March 28, 2026 09:00 ET [TitanPlay Focuses on Player Protection Through Cul...](https://www.globenewswire.com/news-release/2026/03/28/3264178/0/en/TitanPlay-Focuses-on-Player-Protection-Through-Culturally-Aware-Responsible-Gambling-Measures.html "TitanPlay Focuses on...") [](https://www.globenewswire.com/news-release/2026/03/28/3264176/0/en/TxFlow-L1-Mainnet-Launch-Marks-a-New-Phase-for-Multi-Application-On-Chain-Finance.html) March 28, 2026 08:20 ET [TxFlow L1 Mainnet Launch Marks a New Phase for Mul...](https://www.globenewswire.com/news-release/2026/03/28/3264176/0/en/TxFlow-L1-Mainnet-Launch-Marks-a-New-Phase-for-Multi-Application-On-Chain-Finance.html "TxFlow L1 Mainnet...") [](https://www.globenewswire.com/news-release/2026/03/28/3264174/0/en/Rocket-Lab-Successfully-Launches-85th-Mission-and-First-Dedicated-Launch-for-European-Space-Agency.html) March 28, 2026 06:39 ET [Rocket Lab Successfully Launches 85th Mission and ...](https://www.globenewswire.com/news-release/2026/03/28/3264174/0/en/Rocket-Lab-Successfully-Launches-85th-Mission-and-First-Dedicated-Launch-for-European-Space-Agency.html "Rocket Lab...") [](https://www.globenewswire.com/news-release/2026/03/28/3264171/0/en/Cointelegraph-Research-covers-UNDP-s-new-blockchain-report-on-modernizing-public-infrastructure.html) March 28, 2026 02:35 ET [Cointelegraph Research covers UNDP's new blockchai...](https://www.globenewswire.com/news-release/2026/03/28/3264171/0/en/Cointelegraph-Research-covers-UNDP-s-new-blockchain-report-on-modernizing-public-infrastructure.html "Cointelegraph...") [](https://www.globenewswire.com/news-release/2026/03/28/3264162/0/en/THE-CHAMPIONS-COLLECTIVE-PRESENTS-THE-DODGERS-2025-WORLD-SERIES-RING-FEATURING-GAME-SEVEN-DIRT.html) March 27, 2026 21:56 ET [THE CHAMPIONS COLLECTIVE PRESENTS THE DODGERS’ 202...](https://www.globenewswire.com/news-release/2026/03/28/3264162/0/en/THE-CHAMPIONS-COLLECTIVE-PRESENTS-THE-DODGERS-2025-WORLD-SERIES-RING-FEATURING-GAME-SEVEN-DIRT.html "THE CHAMPIONS...") [](https://www.globenewswire.com/news-release/2026/03/28/3264178/0/en/TitanPlay-Focuses-on-Player-Protection-Through-Culturally-Aware-Responsible-Gambling-Measures.html) March 28, 2026 09:00 ET [TitanPlay Focuses on Player Protection Through Cul...](https://www.globenewswire.com/news-release/2026/03/28/3264178/0/en/TitanPlay-Focuses-on-Player-Protection-Through-Culturally-Aware-Responsible-Gambling-Measures.html "TitanPlay Focuses on...") [](https://www.globenewswire.com/news-release/2026/03/28/3264176/0/en/TxFlow-L1-Mainnet-Launch-Marks-a-New-Phase-for-Multi-Application-On-Chain-Finance.html) March 28, 2026 08:20 ET [TxFlow L1 Mainnet Launch Marks a New Phase for Mul...](https://www.globenewswire.com/news-release/2026/03/28/3264176/0/en/TxFlow-L1-Mainnet-Launch-Marks-a-New-Phase-for-Multi-Application-On-Chain-Finance.html "TxFlow L1 Mainnet...") [](https://www.globenewswire.com/news-release/2026/03/28/3264174/0/en/Rocket-Lab-Successfully-Launches-85th-Mission-and-First-Dedicated-Launch-for-European-Space-Agency.html) March 28, 2026 06:39 ET [Rocket Lab Successfully Launches 85th Mission and ...](https://www.globenewswire.com/news-release/2026/03/28/3264174/0/en/Rocket-Lab-Successfully-Launches-85th-Mission-and-First-Dedicated-Launch-for-European-Space-Agency.html "Rocket Lab...") [](https://www.globenewswire.com/news-release/2026/03/28/3264171/0/en/Cointelegraph-Research-covers-UNDP-s-new-blockchain-report-on-modernizing-public-infrastructure.html) March 28, 2026 02:35 ET [Cointelegraph Research covers UNDP's new blockchai...](https://www.globenewswire.com/news-release/2026/03/28/3264171/0/en/Cointelegraph-Research-covers-UNDP-s-new-blockchain-report-on-modernizing-public-infrastructure.html "Cointelegraph...") [](https://www.globenewswire.com/news-release/2026/03/28/3264162/0/en/THE-CHAMPIONS-COLLECTIVE-PRESENTS-THE-DODGERS-2025-WORLD-SERIES-RING-FEATURING-GAME-SEVEN-DIRT.html) March 27, 2026 21:56 ET [THE CHAMPIONS COLLECTIVE PRESENTS THE DODGERS’ 202...](https://www.globenewswire.com/news-release/2026/03/28/3264162/0/en/THE-CHAMPIONS-COLLECTIVE-PRESENTS-THE-DODGERS-2025-WORLD-SERIES-RING-FEATURING-GAME-SEVEN-DIRT.html "THE CHAMPIONS...") Next About Us GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases, financial disclosures and multimedia content to media, investors, and consumers worldwide. Global News - [English](https://www.globenewswire.com/newsroom) - [Français](https://www.globenewswire.com/fr/newsroom) - [Deutsch](https://www.globenewswire.com/de/newsroom) Newswire Distribution Network & Management - [Home](https://www.globenewswire.com/) - [Newsroom](https://www.globenewswire.com/newsroom) - [RSS Feeds](https://www.globenewswire.com/rss/list) - [Notified](https://www.notified.com/) - [Legal](https://www.notified.com/privacy) - [About Us](https://www.globenewswire.com/about) - [Contact Us](https://insight.notified.com/globenewswire-contact-us?utm_medium=Website&utm_source=Contact%20Us&utm_campaign=Contact%20Us%20ENG) - [Resources](https://www.notified.com/resources) © 2026 Digital Media Innovations, LLC. All rights reserved. [GlobeNewswire Linkedin](https://www.linkedin.com/company/1006947 "GlobeNewswire Linkedin") [Notified Twitter](https://twitter.com/Notified "Notified Twitter") ; [Français](https://www.globenewswire.com/fr/news-release/2026/03/29/3264223/0/en/Novartis-IgAN-data-in-New-England-Journal-of-Medicine-show-Fabhalta-slowed-kidney-function-decline-by-49-3.html) [Deutsch](https://www.globenewswire.com/de/news-release/2026/03/29/3264223/0/en/Novartis-IgAN-data-in-New-England-Journal-of-Medicine-show-Fabhalta-slowed-kidney-function-decline-by-49-3.html)
Showing first 1000 characters. Click "Toggle View" to see full content.